Abstract
In daily practice, chemical substances called “direct oral anticoagulants” or DOACs are more convenient to administer when set beside vitamin K antagonists (VKA) due to improved pharmacologic properties, fewer drug interactions and rapid onset of action. The objective of this review was to assess whether DOACs are the alternative for VKA in subjects with mild-to-moderate chronic kidney disease (CKD). An analysis of current DOAC trials and studies was performed focusing on subjects with CKD. This review concludes that although DOACS are not recommended in the course of advanced chronic kidney disease (CrCl<30mL/min) or during dialysis, DOACS are a reasonable choice for individuals with mild to moderate CKD.
Keywords: Anticoagulants, chronic kidney disease, direct oral anticoagulants, vitamin K antagonists, pharmacologic properties, dialysis.
Current Pharmaceutical Design
Title:Safety of New Oral Anticoagulants for Patients with Chronic Kidney Disease
Volume: 24 Issue: 38
Author(s): Krasiński Zbigniew*, Stępak Hubert, Jawień Andrzej and Stanisic Michal
Affiliation:
- Department of Vascular and Endovascular Surgery, Angiology and Phlebology Poznan University of Medical Sciences, Ponzon,Poland
Keywords: Anticoagulants, chronic kidney disease, direct oral anticoagulants, vitamin K antagonists, pharmacologic properties, dialysis.
Abstract: In daily practice, chemical substances called “direct oral anticoagulants” or DOACs are more convenient to administer when set beside vitamin K antagonists (VKA) due to improved pharmacologic properties, fewer drug interactions and rapid onset of action. The objective of this review was to assess whether DOACs are the alternative for VKA in subjects with mild-to-moderate chronic kidney disease (CKD). An analysis of current DOAC trials and studies was performed focusing on subjects with CKD. This review concludes that although DOACS are not recommended in the course of advanced chronic kidney disease (CrCl<30mL/min) or during dialysis, DOACS are a reasonable choice for individuals with mild to moderate CKD.
Export Options
About this article
Cite this article as:
Zbigniew Krasiński *, Hubert Stępak , Andrzej Jawień and Michal Stanisic , Safety of New Oral Anticoagulants for Patients with Chronic Kidney Disease, Current Pharmaceutical Design 2018; 24 (38) . https://dx.doi.org/10.2174/1381612825666190130144051
DOI https://dx.doi.org/10.2174/1381612825666190130144051 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Evolving Role of Radiopharmaceuticals in Hepatocellular Carcinoma Treatment
Anti-Cancer Agents in Medicinal Chemistry Integrin Function and Signaling as Pharmacological Targets in Cardiovascular Diseases and in Cancer
Current Pharmaceutical Design Heparin-Coated Extracorporeal Circulation Systems in Heart Surgery
Recent Patents on Cardiovascular Drug Discovery Acute Ischemic Cerebrovascular Events on Antiplatelet Therapy: What is the Optimal Prevention Strategy?
Current Pharmaceutical Design Platelet GPIIb/IIIa Receptor Antagonists in Human Ischemic Brain Disease
Current Vascular Pharmacology Recent Patents on Hypocholesterolemic Therapeutic Strategies: An Update
Recent Advances in DNA & Gene Sequences (Discontinued) Hematoma Expansion: Clinical and Molecular Predictors and Corresponding Pharmacological Treatment
Current Drug Targets Pharmacogenomics of Oral Antithrombotic Drugs
Current Pharmaceutical Design Sorafenib (BAY 43-9006) in Hepatocellular Carcinoma Patients: From Discovery to Clinical Development
Current Medicinal Chemistry Thrombus Extraction Catheters vs. Angiojet Rheolytic Thrombectomy in Thrombotic Lesions/SV Grafts
Current Cardiology Reviews Prevention and Management of Ovarian Hyperstimulation Syndrome
Current Women`s Health Reviews Cerebrovascular Ultrasonography for Selecting Patients for Stroke Intervention
Recent Patents on CNS Drug Discovery (Discontinued) Use of Oral Direct Factor Xa Inhibiting Anticoagulants in Elective Hip and Knee Arthroplasty: A Meta-analysis of Efficacy and Safety Profiles Compared with those of Low-Molecular-Weight Heparins
Current Vascular Pharmacology Proteoglycan Involvement in Inflammatory Diseases. New Developments in GAG-Based Therapies
Medicinal Chemistry Reviews - Online (Discontinued) Antiangiogenic Therapy in Malignant Glioma: Promise and Challenge
Current Pharmaceutical Design Editorial [Hot Topic: Protease Inhibitors in Drug Discovery (Guest Editor: Francis X. Tavares)]
Current Topics in Medicinal Chemistry Nanocarriers in Improved Heparin Delivery: Recent Updates
Current Pharmaceutical Design Antiangiogenic Therapy for High-Grade Gliomas
CNS & Neurological Disorders - Drug Targets Correlations Between Carotid IMT, Factor VIII Activity Level and Metabolic Disturbances: A Cardio-Vascular Risk Factor in the HIV Positive Persons
Current HIV Research Intra-Graft Abciximab and Verapamil Combined with Direct Stenting is a Safe and Effective Strategy to Prevent Slow-flow and No-Reflow Phenomenon in Saphenous Vein Graft Lesions not Associated with Thrombus
Recent Patents on Cardiovascular Drug Discovery